乐凯胶片股份有限公司2025年年度报告深度解读：亏损扩大、行业压力持续，未来发展面临多重挑战
一、2025年业绩概览
- 营业收入下降：公司2025年实现营业收入13.20亿元，同比下降11.13%。扣除与主营业务无关的收入后，营业收入为12.86亿元，同比下降12.18%。
- 亏损扩大：利润总额为-8,403.60万元（2024年为-5,456.36万元），归属于上市公司股东的净利润为-9,872.82万元，较上年同期亏损进一步扩大。
- 净资产减少：归属于上市公司股东的净资产为23.79亿元，同比下降3.67%。
- 经营活动现金流锐减：2025年经营活动产生的现金流量净额为6,851.46万元，同比下降52.32%。
- 不派发红利：由于公司亏损，2025年度不派发现金红利、不进行资本公积金转增股本、不送红股。
- 母公司未弥补亏损：截至2025年末，母公司累计未分配利润为-2,224.35万元，公司暂不具备利润分配条件。
二、主营业务分析与行业风险
- 业务结构调整压力加大：受国家政策和行业变化影响，医用胶片、光伏产品销量下滑，导致收入和毛利率下滑。医疗行业营业收入下滑23.19%，光伏产品收入大幅下降86.89%，相关毛利率也明显恶化。
- 原材料价格波动风险突出：核心原材料硝酸银因全球供需紧张，价格同比大涨29.43%，显著推高成本（采购成本上升3,423万元）。
- 市场竞争激烈&需求萎缩：医用干式片受“云影像”政策冲击较大，光伏行业整体需求不振，光电与新能源业务虽有所突破但整体压力未减。
- 大客户依赖度适中：前五名客户销售额占比15.87%，但未有单一客户占比超50%，客户结构相对分散。
- 高研发投入且降幅明显：全年研发费用8,784.10万元，同比下降13.54%。公司持续推进高端化、基材自主化、技术降本等创新举措。
- 现金流紧张：经营性现金流同比大幅下降，表明回款压力加大。
三、公司治理与合规风险
- 审计报告为无保留意见：立信会计师事务所出具了标准无保留意见的审计报告，内控审计同样为标准无保留意见。
- 无违规担保及资金占用：报告期内，公司未发生控股股东及其他关联方非经营性资金占用，无违规担保。
- 大额资产受限：截至期末，货币资金中有3.41亿元因票据保证金和专款专用增资款被受限。
- 无重大诉讼、违规及退市风险警示：公司及高管无重大处罚、无重大诉讼，未被实施退市风险警示。
四、前瞻与潜在风险提示
- 行业政策及市场变化风险：医用胶片等传统业务受政策影响较大，未来行业空间和公司盈利能力可能持续承压。
- 原材料价格高位运行：白银价格2025年涨幅达152%，全球供需缺口高企，预计2026年将持续高位运行，成本压力难以缓解。
- 业绩可持续性存疑：公司连续亏损，经营活动现金流持续减少，若未来无法改善，将影响公司持续经营能力。
- 无计划现金分红：公司近三年累计未实施现金分红，短期内投资回报受限。
- 资产减值风险：公司对固定资产等计提了减值准备，未来行业持续下滑可能导致进一步减值。
五、对投资者的影响与关键关注点
- 公司基本面持续恶化：收入和利润双降、现金流紧张、行业景气度低迷，短期内公司基本面难有大幅改善。
- 成本压力与行业风险或影响股价表现：原材料价格飙升、下游需求萎缩、业务结构转型未见成效，可能成为股价下行压力来源。
- 未来盈利能力存较大不确定性：若行业未能复苏或公司无法实现新业务和产品的有效突破，亏损局面或将持续。
- 仍具备上市公司平台、技术与研发等长期优势：公司在技术、质量管控、组织管理等方面依旧具备基础，为后续潜在业务转型和变革留下空间，但短期难以对冲业绩下滑风险。
六、结语
综上，乐凯胶片股份有限公司2025年年报披露出公司经营压力持续加大，亏损幅度扩大，现金流紧张以及行业前景的不确定性。虽然公司具备一定技术与管理优势，但短期业绩难有起色，成本和市场风险高企，投资者需密切关注公司未来经营改善及行业政策变化等关键因素。
免责声明：本文内容仅供参考，不构成任何投资建议。投资有风险，入市需谨慎。投资者应结合自身实际情况与风险承受能力，独立做出投资决策。
LUCKY FILM CO., LTD. 2025 Annual Report Deep Dive: Losses Widen, Industry Headwinds Persist, Multiple Challenges Ahead
I. 2025 Performance Overview
- Revenue Decline: The company reported operating revenue of RMB 1.32 billion for 2025, down 11.13% year-on-year. Operating revenue excluding non-core business income was RMB 1.286 billion, a 12.18% decrease.
- Widening Losses: Total profit was -RMB 84.04 million (2024: -RMB 54.56 million). Net loss attributable to shareholders was -RMB 98.73 million, further deepening from last year.
- Net Assets Shrinking: Shareholders’ equity attributable to listed company shareholders was RMB 2.379 billion, down 3.67% year-on-year.
- Cash Flow Under Pressure: Net cash flow from operating activities was RMB 68.51 million, down 52.32% year-on-year.
- No Dividend: Due to losses, no cash dividend or bonus shares will be distributed for 2025.
- Accumulated Losses: The parent company had an accumulated undistributed loss of RMB -22.24 million at year-end, making it ineligible for profit distribution.
II. Business Analysis & Industry Risks
- Business Structure Under Pressure: Medical film and photovoltaic product sales declined due to policy and industry changes, impacting both revenue and gross margin. Medical business revenue fell 23.19%, and PV revenue plummeted by 86.89% with sharp margin deterioration.
- Raw Material Price Volatility: Key raw material silver nitrate soared by 29.43% due to global shortages, pushing up procurement costs by RMB 34.23 million.
- Intense Competition & Demand Contraction: Medical dry film was heavily impacted by government “cloud imaging” policies; PV sector demand remained weak; while new business lines made some progress, overall pressure persisted.
- Moderate Customer Concentration: Top five customers accounted for 15.87% of sales, with no single client above 50%—customer base is relatively diversified.
- R&D Investment Down: R&D expenses were RMB 87.84 million, down 13.54%. The company continues to push for high-end, localized materials and technology cost reduction.
- Tightening Cash Flows: Substantial decline in operating cash flow, highlighting intensified collection pressure.
III. Corporate Governance & Compliance Risks
- Unqualified Audit Opinion: Audit and internal control reports from Lixin CPA are standard unqualified.
- No Irregular Guarantees or Fund Occupation: No non-operational fund occupation or irregular guarantees by controlling shareholders.
- Significant Restricted Assets: RMB 341 million in restricted cash due to bill guarantees and capital increases.
- No Major Lawsuits or Delisting Risk: No major litigation, penalties, or delisting risk warning for the company or management.
IV. Forward-Looking Risks
- Policy & Market Risks: Traditional business segments face ongoing policy headwinds, with uncertain industry prospects and profitability.
- Persistently High Raw Material Costs: Silver prices rose 152% in 2025; supply/demand gap is expected to keep prices high in 2026, sustaining cost pressures.
- Sustainability Doubts: Continuing losses and shrinking operating cash flows could threaten ongoing operations if unaddressed.
- No Dividend Plan: No cash dividend distributed in the past three years, limiting shareholder returns in the near term.
- Asset Impairment Risks: Impairments have been recognized for fixed assets, with potential for further write-downs if the industry downturn continues.
V. Investor Implications & Key Points
- Deteriorating Fundamentals: Ongoing revenue/profit declines, tight cash flow, and poor industry outlook—short-term turnaround is unlikely.
- Cost & Industry Risks May Pressure Stock Price: Surging costs, demand contraction, and slow business transition are likely stock overhangs.
- Profitability Uncertainty: If the industry does not recover or the company cannot achieve a breakthrough in new business/products, losses could persist.
- Long-Term Platform & Technology Advantages: The company’s technical, quality, and management strengths offer a foundation for future reform, but cannot offset short-term performance risks.
VI. Conclusion
In summary, Lucky Film Co., Ltd.’s 2025 annual report reveals mounting operational pressure, widening losses, tightening liquidity, and uncertain industry outlook. While the company retains certain technological and management strengths, its fundamentals remain weak in the near term, and cost and market risks are elevated. Investors should watch for signs of operational improvement and industry policy shifts.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investments involve risks; please make decisions prudently based on your individual circumstances and risk tolerance.
View 乐凯胶片 Historical chart here
